Nimodipine on the clinical course of patients with acute ischemic stroke


Phase N/A Results

Trial Description

To determine whether treatment with the calcium antagonist nimodipine would reduce neurological deficit in acute ischemic stroke patients.


  • Nimodipine (NimotopĀ®)Drug
    Other Names: The treatment group
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Prospective, single-blind, controlled trial of 60 patients at a single center.

Patient Involvement

Patients were randomized to receive nimodipine (120 mg/d in 3 divided doses) or standard treatment alone for 28 days. Standard treatment consisted of 10% depolymerized dextran 12h/d for 5 days. Digitalis, antihypertensive medication, antibiotics and heparin were administered as needed. Patients did not receive follow-up evaluations.


Type Measure Time Frame Safety Issue
Primary Mathew sum score on days 1, 2, 3, 5, 7, 14, 21, and 28 of treatment.
Secondary Physician's assessment.